Keywords: ph, ii, data, show, tasigna, potential, front-line

Ph II data show Tasigna's potential in front-line CML

Article | 08 June 2009

New data show that, at 12 months, newly-diagnosed patients taking Swiss drug major Novartis' Tasigna (nilotinib) to treat a life-threatening form ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing